{
    "nctId": "NCT02532400",
    "briefTitle": "Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients",
    "officialTitle": "Comparison of Neoadjuvant Aromatase Inhibitors With Ovarian Suppression Versus Chemotherapy in Premenopausal Patients With Hormone Receptor-positive Breast Cancer (COMPETE): a Randomized Phase 3 Trial",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 21,
    "primaryOutcomeMeasure": "Overall response rate(ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Written informed consent\n2. Women aged \u2265 18 years\n3. Histologically confirmed invasive breast cancer\n4. American Joint Committee on Cancer (AJCC) stage: \u2161A-\u2162C, no evidence of metastasis\n5. At least one measurable disease in breast and/or axilla\n6. ER and/or progesterone receptor(PgR) positive(\u226510% of the cells by IHC)\n7. HER2 negative(by IHC and/or FISH)\n8. Premenopause status (estradiol in premenopausal range or with normal menstrual cycle in the past 6 months with no use of hormonal drugs)\n9. Eastern Cooperative Oncology Group\uff08ECOG\uff09score 0-1, an estimated life expectancy of at least 12 months\n10. Adequate bone marrow function: Leukocyte \u2265 3.0\\*109/L; Neutrophil \u2265 1.5\\*109/L; Hb \u2265 100g/L; Platelet(PLT\uff09 \u2265 80\\*109/L\n11. Adequate liver, renal function and coagulation function: Alanine transaminase\uff08ALT\uff09 and/or Aspartate transaminase\uff08AST\uff09\u2264 1.5 upper normal limit\uff08UNL\uff09, total bilirubin \u2264upper normal limit, creatinine \u2264 110umol/L, Creatinine clearance \\> 60ml/min, blood urea nitrogen\uff08BUN\uff09 \u2264 7.1mmol/L, activated partial thromboplastin time\uff08APTT\uff09 \u2264 1.5 upper normal limit\uff08UNL\uff09\n12. Women with child-bearing potential must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study\n13. Serological records of hepatitis B virus\uff08HBV\uff09and hepatitis C virus\uff08HCV\uff09 testing.\n\nExclusion Criteria:\n\n1. Stage IV breast cancer\n2. Prior systemic or loco-regional treatment of breast cancer\n3. Any anti-neoplastic treatment within 28 days before the beginning of study\n4. Known severe hypersensitivity to any drugs in this study\n5. History of malignancy within 5 years except carcinoma in situ of cervix or skin basal cell carcinoma that had received adequate treatment\n6. Peripheral neuropathy \u2265 2\u00b0, according to National Cancer Institute(NCI) Common Terminology Criteria for Adverse Events(CTCAE)(Version 4.0)\n7. Any cardiac or pulmonary dysfunction defined as following:\n\n(1) \u2265 3\u00b0 symptomatic congestive heart failure (CHF) according to NCI CTCAE(Version 4.0) or \u2265 2\u00b0 CHF according to New York Heart Association\uff08NYHA\uff09\n\n(2) Angina that needs anti-anginal drugs, advanced conduction abnormality or significant vascular disease\n\n(3) Uncontrolled high-risk arrhythmia: atrial tachycardia that silent heart rate \\>100/min, significant ventricular arrythmia or advanced atrioventricular block(2\u00b0 type II atrioventricular or 3\u00b0 atrioventricular block)\n\n(4) Poorly controlled hypertension (systolic BP \\> 180 mmHg or diastolic BP \\> 100 mmHg)\n\n(5) Transmural myocardial infarction in EKG\n\n(6) Long-term oxygen therapy\n\n8. Uncontrolled severe systemic disease(clinically significant cardiovascular disease\uff0cpulmonary disease or metabolic disease, wound healing disorder, ulcer, severe infection)\n\n9. Pregnant or breast feeding\n\n10. Major operation, obvious trauma within 28 days before randomization or planned major operation during the study\n\n11. Known active hepatic disease due to hepatitis B virus, hepatitis C virus, auto-immune liver disease or sclerosing cholangitis\n\n12. Known HIV infection\n\n13. Any reasons investigators consider that not suitable for the study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}